{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:18:24Z","timestamp":1787739504853,"version":"build-2784847793"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Although high PD-L1 expression correlates with improved outcomes to immune checkpoint inhibitor (ICI), it remains an imperfect predictive biomarker. DNA damage response (DDR) pathway alterations are closely associated with antitumor immunity, shaping tumor immunogenicity and the immune microenvironment. This study evaluates the distribution and clinical impact of DDR alterations in advanced Non-small cell lung cancer (NSCLC) with Programmed death-ligand 1 (PD-L1) \u2265 50%, providing insights for personalized treatment selection and response prediction. Experimental Design: Patients with advanced NSCLC and PD-L1 expression \u2265 50% who received first-line ICI-based therapy were retrospectively enrolled. Tumor tissue samples underwent targeted next-generation sequencing using a comprehensive cancer panel, with a predefined 35-gene DDR panel used to identify and classify pathogenic or likely pathogenic DDR alterations. The associations between genomic DDR alteration status, clinicopathologic characteristics, cytokine profiles, and immunotherapy outcomes were evaluated. Results: Among 121 patients, 72 (59.5%) were classified as DDR-positive and 49 (40.5%) as DDR-negative based on genomic DDR alterations. DDR-positive patients exhibited a higher burden of DDR alterations and TMB, and DDR-positive status remained independently associated with improved outcomes after adjustment for clinical factors and TMB. DDR-positive patients had higher DCB rates and IL-2 levels, whereas TNF-\u03b1 and IL-6 levels were elevated in DDR-negative patients. DDR-positive status was associated with longer PFS than DDR-negative status (median, 12.7 vs. 8.9 months), with the benefit of chemo-immunotherapy mainly observed in DDR-positive patients. Conclusions: Genomic DDR alterations are associated with distinct immune profiles and may represent a potential biomarker for immunotherapy stratification. DDR-positive patients may derive greater benefit from chemo-immunotherapy, supporting further prospective investigation.<\/jats:p>","DOI":"10.3390\/curroncol33090508","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:05:46Z","timestamp":1787735146000},"page":"508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA Damage Response Alterations Stratify Response to ICI-Based Therapy in Advanced NSCLC with High PD-L1 Expression"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-3585","authenticated-orcid":false,"given":"Fang","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-1001","authenticated-orcid":false,"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of Non-Small-Cell Lung Cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"114519","DOI":"10.1016\/j.intimp.2025.114519","article-title":"Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy","volume":"155","author":"Tarin","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients with Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"Kudaba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated Overall Survival Analysis from IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: Developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Smolarz, B., \u0141ukasiewicz, H., Samulak, D., Piekarska, E., Ko\u0142aci\u0144ski, R., and Romanowicz, H. (2025). Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052049"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: Lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lou, S., Wang, Y., Zhang, J., Yin, X., Zhang, Y., Wang, Y., and Xue, Y. (2022). Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.806324"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","article-title":"The complementarity of DDR, nucleic acids and anti-tumour immunity","volume":"619","author":"Kornepati","year":"2023","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-010-9443-1","article-title":"Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis","volume":"28","author":"Wei","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Carlsen, L., and El-Deiry, W.S. (2022). Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.998388"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Knelson, E.H., Patel, S.A., and Sands, J.M. (2021). PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses. Cancers, 13.","DOI":"10.3390\/cancers13040727"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mani, M., Park, J.W., and Martin, T.F.J. (2025). Regulatory Mechanisms and Therapeutic Targeting of PD-L1 Trafficking and Stability in Cancer Immunotherapy. Cancers, 17.","DOI":"10.3390\/cancers17111747"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/1754-9485.13413","article-title":"Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy","volume":"66","author":"Czajkowski","year":"2022","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lee, E.C.Y., Kok, J.S.T., Teh, B.T., and Lim, K.S. (2022). Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113356"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA Damage and Cancer Immunotherapy: A STING in the Tale","volume":"80","author":"Groelly","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e010612","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","article-title":"SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion","volume":"187","author":"Leuzzi","year":"2024","journal-title":"Cell"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:25:39Z","timestamp":1787736339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090508"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090508","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}